DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals
Advanced Science · 2025
DOI: 10.1002/advs.202416958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiashuo Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. Hauptthemen laut MEDLINE: Deep Learning, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Accurate characterization of cellular states is the foundation for precise prediction of drug sensitivity in cancer cell lines, which in turn is fundamental to realizing precision oncology. However, current deep learning approaches have limitations in characterizing cellular states. They rely solely on isolated genetic markers, overlooking the complex regulatory networks and cellular mechanisms that underlie drug responses. To address this limitation, this work proposes DeepCCDS, a Deep learning framework for Cancer Cell Drug Sensitivity prediction through Characterizing Cancer Driver Signals. DeepCCDS incorporates a prior knowledge network to characterize cancer driver signals, building upon the self‐supervised neural network framework. The signals can reflect key mechanisms influencing cancer cell development and drug response, enhancing the model's predictive performance and interpretability. DeepCCDS has demonstrated superior performance in predicting drug sensitivity compared to previous state‐of‐the‐art approaches across multiple datasets. Benefiting from integrating prior knowledge, DeepCCDS exhibits powerful feature representation capabilities and interpretability. Based on these feature representations, we have identified embedding features that could potentially be used for drug screening in new indications. Further, this work demonstrates the applicability of DeepCCDS on solid tumor samples from The Cancer Genome Atlas. This work believes integrating DeepCCDS into clinical decision‐making processes can potentially improve the selection of personalized treatment strategies for cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
- College of Basic Medical Science, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
ORCID-Profile: Jiashuo Wu, Junwei Han
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Wu, J., Lai, J., Zhao, X., Wang, Z., Zhang, Y., Wang, L., Su, Y., He, Y., Li, S., Jiang, Y., & Han, J. (2025). DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals. Advanced Science. https://doi.org/10.1002/advs.202416958
Vancouver
Wu J, Lai J, Zhao X, Wang Z, Zhang Y, Wang L, et al. DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals. Advanced Science. 2025. doi:10.1002/advs.202416958
BibTeX
@article{Wu2025,
author = {Wu, Jiashuo and Lai, Jiyin and Zhao, Xilong and Wang, Ziyi and Zhang, Yongbao and Wang, Liqiang and Su, Yinchun and He, Yalan and Li, Siyuan and Jiang, Ying and Han, Junwei},
title = {DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202416958}
}
EUVIMED